Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, Lee JS, Pang YK, Cobo M, Kasahara K, Cheng Y, Nogami N, Cho EK, Su WC, Zhang G, Huang X, Li-Sucholeiki X, Lentrichia B, Dearden S, Jenkins S, Saggese M, Rukazenkov Y, Ramalingam SS. Gray JE, et al. Among authors: kasahara k. Clin Cancer Res. 2019 Nov 15;25(22):6644-6652. doi: 10.1158/1078-0432.CCR-19-1126. Epub 2019 Aug 22. Clin Cancer Res. 2019. PMID: 31439584 Free PMC article.
Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Ohyanagi F, Taguchi F, Horai T, Kasahara K, Takeda Y, Shibata K, Shirosaki H, Nishio M. Ohyanagi F, et al. Among authors: kasahara k. Jpn J Clin Oncol. 2006 Sep;36(9):547-51. doi: 10.1093/jjco/hyl062. Epub 2006 Jul 26. Jpn J Clin Oncol. 2006. PMID: 16870693 Clinical Trial.
Bi-weekly administration of gemcitabine plus vinorelbine in elderly patients with advanced non-small-cell lung cancer: multicenter phase II trial.
Araya T, Kasahara K, Kimura H, Shibata K, Kita T, Shirasaki H, Hara J, Yoshimi Y, Sone T, Oribe Y, Nobata K, Nishi K, Fujimura M, Nakao S; Kanazawa Lung Cancer Chemotherapy Group. Araya T, et al. Among authors: kasahara k. Lung Cancer. 2007 Jun;56(3):371-6. doi: 10.1016/j.lungcan.2007.01.001. Epub 2007 Feb 14. Lung Cancer. 2007. PMID: 17300851 Clinical Trial.
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
Kimura H, Kasahara K, Shibata K, Sone T, Yoshimoto A, Kita T, Ichikawa Y, Waseda Y, Watanabe K, Shiarasaki H, Ishiura Y, Mizuguchi M, Nakatsumi Y, Kashii T, Kobayashi M, Kunitoh H, Tamura T, Nishio K, Fujimura M, Nakao S. Kimura H, et al. Among authors: kasahara k. J Thorac Oncol. 2006 Mar;1(3):260-7. doi: 10.1016/s1556-0864(15)31577-x. J Thorac Oncol. 2006. PMID: 17409866 Free article. Clinical Trial.
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA Jr, Carbone DP. Taguchi F, et al. Among authors: kasahara k. J Natl Cancer Inst. 2007 Jun 6;99(11):838-46. doi: 10.1093/jnci/djk195. J Natl Cancer Inst. 2007. PMID: 17551144
Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.
Kasahara K, Arao T, Sakai K, Matsumoto K, Sakai A, Kimura H, Sone T, Horiike A, Nishio M, Ohira T, Ikeda N, Yamanaka T, Saijo N, Nishio K. Kasahara K, et al. Clin Cancer Res. 2010 Sep 15;16(18):4616-24. doi: 10.1158/1078-0432.CCR-10-0383. Epub 2010 Aug 2. Clin Cancer Res. 2010. PMID: 20679350
1,334 results